mardi 22 mai 2018

Onco Actu du 22 mai 2018

1. Biologie

New Insights into Why and How Multiple Myeloma Arises [Cancer Research Catalyst]

Every Cell in Your Body Has the Same DNA. Except It Doesn’t. [NY Times]

2.6 Etiologie - Environnement

Ultra-clean homes could trigger childhood leukaemia, major review suggests [The Telegraph]

Missing microbes 'cause' childhood cancer [BBC News]

Infection theory could explain cause of common childhood leukaemia, says scientist [Cancer Research UK]

Could childhood leukaemia become a thing of the past? [Institute of Cancer Research]

Most common childhood cancer 'partly caused by lack of infection' [The Guardian]

4. Dépistage, diagnostic et pronostic

Vanderbilt’s Alvarez: Gynecologists must properly assess all patients for cancer before surgery [The Cancer Letter]

Gynecology’s deadly surprise: Cancers are frequently missed prior to routine procedures [The Cancer Letter]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Direct-to-Consumer Genetic Testing [JAMA]

4.12 Biopsies liquides

Early detection: a long road ahead [Nature Reviews Cancer]

4.15 Dép., diag. & prono. - imagerie

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas [Mass. General Hospital]

Publication of the Strategic Review of Bioimaging in the UK [BBSRC]

5. Traitements

Improving Survival in Pancreatic Cancer with Platinum-Based Chemotherapy [Johns Hopkins]

Article in NY Times describes how we might learn cancer cures from "Exceptional Responders" [Vinay Prasad]

New Cancer Treatments Lie Hidden Under Mountains of Paperwork [NY Times]

5.10 Traitements - Essais

Ovarian Cancer Drug Shows Promise in Pancreatic Cancer Patients with BRCA Mutation [Penn Medicine]

5.12 Immunothérapies

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy [FDA]

5.12.5 Immunothérapies - Pharma

Dendreon Initiates Large-Scale Clinical Trial to Investigate PROVENGE® (sipuleucel-T) in Men with Early-Stage Prostate Cancer on Active Surveillance [Dendreon]

5.2 Pharma

ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer [Janssen]

Forget RNA drugs. Accent gets $40M to develop small molecules that modify RNA instead [EndPoints]

5.2.1 Pharma - Partenariats

Wrestling with setbacks, Celgene adds $65M discovery alliance with Evotec to beef up on new cancer drugs [EndPoints]

5.2.3 Pharma - économie

Bay Area startup Rain Therapeutics nabs $18M Series A to target lung cancer niche [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA Approves Daratumumab for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible [ESMO]

5.5.8 ASCO (poumon)

ASCO pumps up a one-sided view of lung cancer screening: Here’s what most of the coverage missed [HealthNewsReview]

6.10 Politiques

UK’s powerful funding body takes shape [Nature]

6.10.1 Politiques (USA)

For cancer patients, Trump’s drug pricing proposal falls short [STAT]

Trump official on defensive as critics scoff at drug plan [The Hill]

6.7 DMP, Big Data & applis

More patients are taking home recordings of their doctor visits. But who else could listen? [STAT]

6.7.1 IA/bioinformatique

Ethical, Social and Political Challenges of Artificial Interlligence in Health [Future Advocacy]

PM May challenges scientists to help transform Britain after Brexit [Reuters]

The Guardian view on AI in the NHS: a good servant, when it’s not a bad master [The Guardian]

May to pledge millions to AI research assisting early cancer diagnosis [The Guardian]